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Metabolite annotation and identification are primary challenges in untargeted
metabolomics experiments. Rigorous workflows for reliable annotation of mass features
with chemical structures or compound classes are needed to enhance the power of untar-
geted mass spectrometry. High-resolution mass spectrometry considerably improves the
confidence in assigning elemental formulas to mass features in comparison to nominal
mass spectrometry, and embedding of fragmentation methods enables more reliable
metabolite annotations and facilitates metabolite classification. However, the analysis of
mass fragmentation spectra can be a time-consuming step and requires expert knowledge.
This study demonstrates how characteristic fragmentations, specific to compound classes,
can be used to systematically analyze their presence in complex biological extracts like
urine that have undergone untargeted mass spectrometry combined with data dependent
or targeted fragmentation. Human urine extracts were analyzed using normal phase liquid
chromatography (hydrophilic interaction chromatography) coupled to an Ion Trap-Orbitrap
hybrid instrument. Subsequently, mass chromatograms and collision-induced dissociation
and higher-energy collisional dissociation (HCD) fragments were annotated using the freely
available MAGMa software1. Acylcarnitines play a central role in energy metabolism by
transporting fatty acids into the mitochondrial matrix. By filtering on a combination of a
mass fragment and neutral loss designed based on the MAGMa fragment annotations,
we were able to classify and annotate 50 acylcarnitines in human urine extracts, based on
high-resolution mass spectrometry HCD fragmentation spectra at different energies for all
of them. Of these annotated acylcarnitines, 31 are not described in HMDB yet and for only
4 annotated acylcarnitines the fragmentation spectra could be matched to reference spec-
tra. Therefore, we conclude that the use of mass fragmentation filters within the context
of untargeted metabolomics experiments is a valuable tool to enhance the annotation of
small metabolites.
Keywords: high-resolution mass spectrometry, collisional fragmentation, metabolite annotation, classification,
acylcarnitines, human urine, HILIC chromatography, metabolomics
INTRODUCTION
Mass spectrometry in conjunction with liquid chromatography
has been successfully used for two decades to profile extracts of
complex biological samples. In recent years, the ability to identify
and annotate hundreds of compounds simultaneously in a single
sample has been a major driving force behind the expansion of
the technology known as metabolomics (Dunn et al., 2013). How-
ever, assigning molecular structures to detected mass signals has
proven to be a primary challenge in metabolomics studies (Van
Der Hooft et al., 2013). Modern mass spectrometers are capable of
capturing the molecular masses of ionized metabolites at high-
resolution, providing scientists with an unprecedented insight
in complex biological mixtures such as cell extracts, plasma, or
1http://www.emetabolomics.org
urine. High-resolution mass spectrometers such as the orbitrap
provide accurate mass measurements and are thus able to reli-
ably distinguish co-eluting isobaric species of marginally different
mass (Watson and Sparkman, 2007; Makarov and Scigelova, 2010),
in contrast to mass spectrometers with nominal mass detection.
Furthermore, many modern mass spectrometers can trap ionized
metabolites in collision cells and generate fragments that can be
analyzed at high-resolution too (Schuhmann et al., 2011; Van Der
Hooft et al., 2011, 2012b). Analysis of the resulting fragments and
neutral losses usually provides additional structural information
about the fragmented mass as well as more constraints for its
elemental formula.
Recent studies have demonstrated the use of an ion trap – orbi-
trap hybrid mass spectrometer to fragment reference compounds
or metabolites present in biological extracts (Kasper et al., 2012;
Rojas-Cherto et al., 2012;Van Der Hooft et al., 2012a). Two types of
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fragmentation are commonly employed in metabolomics studies:
collision induced dissociation (CID) or higher-energy collisional
dissociation (HCD), each of them usually providing slightly dif-
ferent fragmentation spectra for the same fragmented metabolite.
High-resolution mass spectrometry combined with fragmentation
greatly enhances our ability to structurally elucidate compounds,
but assigning a chemical annotation to observed mass features
remains a major bottleneck when using untargeted metabolomics
approaches (Kind and Fiehn, 2010; Wishart, 2011; Dunn et al.,
2013; Van Der Hooft et al., 2013).
Although untargeted metabolomics studies aspire to capture
and characterize the entire metabolome of a biological sample, in
practice trade-offs are made during sample preparation and mass
detection as to which metabolites are actually measured. Complex
urine extracts prepared for “normal phase” chromatography (i.e.,
hydrophilic interaction chromatography, HILIC) typically contain
several thousands of small polar metabolites covering multiple
chemical classes that can be separated and detected in a mass chro-
matogram (Creek et al., 2011; Zhang et al., 2012). Here, we describe
the annotation of multiple detected acylcarnitines using global
HILIC – high-resolution tandem mass spectrometry approaches.
Acylcarnitines are all derivatives of carnitine, carrying different
fatty acids (Thompson et al., 2012). These metabolites play an
important role in energy metabolism, for example, by transport-
ing acyl moieties into the mitochondria where they undergo beta
oxidation, and specific enzymes and transporter proteins exist that
translocate acylcarnitines in and out of the cells and blood stream
and excessive acylcarnitines are excreted in the urine (Frayn, 2010).
Acylcarnitine concentrations vary depending on the energy status
of the human body (Thompson et al., 2012). Irregular urinary
and serum acylcarnitine patterns have been identified as biomark-
ers for several energy related diseases including diabetes mellitus
(Dudzik et al., 2014) and metabolic syndrome (Patterson et al.,
2009; Peng et al., 2013a). Moreover, acylcarnitine patterns were
found to be markers for inborn metabolic distortions caused by
malfunctioning of enzymes involved in fatty acid metabolism (Ellis
et al., 2007; Gucciardi et al., 2012).
Both reversed phase (C18 based) and HILIC chromatography,
often combined with dedicated sample preparation, have been
used to separate acylcarnitines from other urinary metabolites
and from each other (Yang et al., 2007; Gucciardi et al., 2012;
Peng et al., 2013b). Gas chromatography coupled to mass spec-
trometry has also been used successfully to detect and characterize
acylcarnitine species (Libert et al., 2000). The most comprehen-
sive study on acylcarnitine species in urine up to date reported
over 350 species using a 2 h UPLC run following sample prepara-
tion focused specifically on this class of compound, and a targeted
nominal mass fragmentation approach (Zuniga and Li, 2011). In
contrast, untargeted mass spectrometry experiments aim to iden-
tify a diverse spectrum of compounds without being optimized for
particular chemical classes. Within this context, the use of colli-
sion induced fragmentation of metabolites to assess their structure
can serve as a means of annotating substructures or structures to
metabolites in complex mixtures. The aim of this study was to
explore the use of data dependent and targeted CID and HCD
fragmentation in combination with a generic pHILIC or HILIC
gradient coupled to untargeted high-resolution mass spectrometry
to classify and annotate acylcarnitines present among the broad
spectrum of polar metabolites that can be detected in human urine
extracts. Furthermore, the generated high-resolution fragmenta-
tion spectra were used to obtain structural information on the
fatty acyl-moiety linked to the carnitine molecule.
Fragmentation spectra obtained from urine extracts were first
annotated using the MAGMa software developed by Ridder et al.
(2014a) (see text footnote 1) with potential candidates from a
compound database containing known and predicted human
metabolites (HMDB)2. Then, based on fragment annotation as
proposed by the MAGMa software and as proposed in literature,
key fragments, or losses were determined in order to create a mass
fragmentation filter that uniquely screens for the acylcarnitine
structures. Subsequently, CID-MSn and HCD type fragmentation
files were manually studied to assess the designed filter for acyl-
carnitine classification. Next, the mass fragmentation filter was
used to annotate acylcarnitines fragmented by data dependent and
independent fragmentation. A graphical outline of the approach
is presented in Figure 1. All acylcarnitine species that could be
annotated in the pHILIC and HILIC gradients are listed in Table
S1 in Supplementary Material.
MATERIALS AND METHODS
MATERIALS
HPLC-grade methanol, acetonitrile, isopropanol, and analyti-
cal reagent grade chloroform were acquired from Fisher Scien-
tific, Loughborough, UK. HPLC-grade H2O was purchased from
VWR Chemicals, Fountenay-sous-Bois, France. Formic acid (for
mass spectrometry) and ammonium carbonate were acquired
from Fluka Analytical (Sigma-Aldrich), Steinheim, Germany. l-
carnitine (≥98%) was obtained from Sigma-Aldrich, St. Louis,
MO, USA.
Urine samples from anonymized healthy human volunteers
were used from a clinical data set in the Glasgow Polyomics
archive. The seven urine samples used in this study were num-
bered 1–7, urines 1–4 were used for data-dependent fragmentation
approaches, where urines 5–7 were used for targeted fragmenta-
tion of suspected low abundant acylcarnitines, as summarized in
Table 1.
METHODS
L-carnitine solution for direct infusion
From a 100 mM solution in H2O, 15µL was mixed with 5µL iso-
propanol in a 96 wells-plate to yield a final 75 mM l-carnitine
solution.
Urine sample preparations
A general metabolome extraction procedure was performed: (i)
5µL urine was extracted in 200µL chloroform/methanol/water
(1:3:1) at 4°C; (ii) then vortexed for 5 min at 4°C; (iii) then cen-
trifuged for 3 min (13,000× g ) at 4°C. The resulting supernatant
was stored at−80°C until analysis.
NanoMate direct infusion measurements
To allow for sufficient spray time for extensive fragmentation
experiments, a chip-based nano electrospray (Triversa NanoMate,
2www.hmdb.ca
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FIGURE 1 | Graphical representation of the described data analysis
approach, starting from top left following the arrows to the bottom
right: untargeted mass chromatogram, fragmentation data
acquisition, HMDB annotation and fragment annotation in MAGMa
to find specific mass fragments and neutral losses for
acylcarnitines, mass fragmentation filter and the structure of
carnitine, extracted ion chromatogram and neutral loss trace for the
acylcarnitine filter, extracted ion chromatogram and spectrum for a
detected acylcarnitine, and an example acylcarnitine (conjugate of
sebabic acid).
Table 1 | Schematic experimental design of human urines used in this
study.
Urine # Chromatography Mass spectrometry Usage
1 pHILIC Untargeted Filter generation and
application
2 pHILIC Untargeted Filter generation and
application
3 HILIC Untargeted Filter application
4 HILIC Untargeted Filter application
5 HILIC Targeted Filter application
6 HILIC Targeted Filter application
7 HILIC Targeted Filter application
These samples were obtained as part of an ethical approved project, granted
by the MVLS College Ethics Committee of the University of Glasgow, Glas-
gow, UK (Project No: 2012061).The volunteers gave their consent for conducting
metabolomics studies with their urine samples.
Advion, USA) source was used in infusion mode with a set up as
described previously (Van Der Hooft et al., 2011). The key set-
tings were positive ionization mode, sample volume of 10µL, a
gas pressure of 0.5 psi, and a voltage of 1.5 kV, with a data acqui-
sition delay of 0.5 min. Orbitrap Elite FTMS mass spectrometry
settings: AGC 1× 106 (full scan mode) and 5× 104 (MSn mode),
capillary temperature 220°C, source voltage +1.6 kV, source cur-
rent 100µA, S-lens RF 65.5%, skimmer offset 0 V, 1 microscan,
and the mass spectrometer was calibrated with Thermo calmix
and tuned on m/z 195.10 (caffeine). Full scan data were acquired
for 1 min to check signal intensity and purity of the sample.
MS2 fragmentation spectra were obtained for 5 min in positive
ionization mode using CID and HCD fragmentation modes from
10 to 200 normalized collision energy (NCE), in steps of 10 NCE.
Further key settings were isolation width of 3.0 Da, minimum sig-
nal required of 4500, first mass fixed at 50.00 m/z (HCD), and
additional microscans and AGC targets were 2 and 0 (MS2), 4 and
2× 106 (MS3), and 6 and 3× 106 (MS4), respectively.
HILIC-MS/MS
The LC separation was performed using HILIC (Creek et al., 2011),
using the following equipment, gradients, and settings:
(i) ZIC-pHILIC 150 mm× 4.6 mm, 5µm column (Merck
Sequant) equipped with the corresponding pre-column, oper-
ated by an UltiMate 3000 RSLCnano liquid chromatography
system (Dionex, Camberley, Surrey, UK). The LC mobile
phase was a linear biphasic gradient from 80% B to 20% B over
15 min, followed by a 2 min wash with 5% B, and 8 min re-
equilibration with 80% B, where solvent B is acetonitrile and
solvent A is 20 mM ammonium carbonate in water. The flow
rate was 300µL/min, column temperature was held at 35°C,
injection volume was 10µL, and samples were maintained at
4°C in the autosampler.
(ii) ZIC-HILIC 150 mm× 2.1 mm, 3.5µm column (Merck
Sequant) equipped with the corresponding pre-column, oper-
ated by an UltiMate 3000 RSLCnano liquid chromatography
system (Dionex, Camberley, Surrey, UK). The LC mobile
phase was a biphasic linear gradient from 80% B to 20%
B over 30 min, followed by an 8 min wash with 5% B, and
8 min re-equilibration with 80% B, where solvent B is 0.08%
formic acid in acetonitrile and solvent A is 0.1% formic acid
in water. The flow rate was 100µL/min, column temperature
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was held at 35°C, injection volume was 10µL, and samples
were maintained at 4°C in the autosampler.
The Orbitrap Elite mass spectrometer was calibrated using
Thermo calibration mix in positive ionization mode and tuned
on m/z 195.10 (caffeine). Source mass spectrometry settings for
both ZIC-HILIC and ZIC-pHILIC in positive ionization mode
were as follows: a HESI 2 probe was used with AGC 1× 106 (full
scan mode) and 5× 104 (MSn mode), sheath gas 10 a.u., auxil-
iary gas 5 a.u., sweep gas 1 a.u., source heater temperature 150°C,
capillary temperature 275°C, source voltage+4 kV, source current
100µA, S-lens RF 50%, skimmer offset 0 V, maximum ion times
of 100 ms (full scan mode) and 200 ms (MSn mode), and all scans
consist of 1 microscan.
Data-dependent ZIC-pHILIC-MS/MS and MSn: data were
obtained in profile mode, for full scans the m/z window was 70.00–
1000.00 and the resolution was set to 240,000. For fragmentation
experiments, key settings were: isolation width of 1.0 Da, mini-
mum signal required of 500, first mass fixed at 50.00 m/z (HCD),
and a dynamic exclusion of 48 s. A rejection list was included
with the top 15 most intense ions encountered in blank injections
preceding the fragmentation runs to reduce the number of non-
informative fragmentation spectra. HCD fragmentation spectra
of the most intense ion (data-dependent acquisition) in the full
scan were obtained at 30, 70, and 110 NCE. CID-MSn (n≤ 3) frag-
mentation was performed as in (Van Der Hooft et al., 2012b), but
using 45 NCE.
Data-dependent ZIC-HILIC-MS/MS: as for ZIC-pHILIC-MS,
with a resolution set to 120,000 for full scan mode, and 15,000
for MS ≥2.
Targeted ZIC-HILIC-MS/MS: as for ZIC-pHILIC-MS/MS,
with a parent ion list including masses of potential acylcarni-
tine structures with retention times comparable to previously
annotated acylcarnitine structures in the data-dependent HILIC-
MS/MS runs of urine 3 and 4, i.e., eluting between 5 and 7 min.
The parent ion lists for urine extracts 5–7 included in total 27
masses not previously fragmented and annotated in urines 1–4 for
which the most probable elemental formula matches CxHyNOz,
i.e., comprising of one nitrogen atom and no other elements
than carbon, hydrogen, and oxygen. The structure of the MS/MS
method was as follows: one full scan, followed by fragmentation
at 30, 70, and 110 NCE of the two most intense ions present at
the parent ion list (i.e., no fragmentation took place if no targeted
ions were present above the threshold).
Prior to the hyphenated MS fragmentation experiments, a
series of four blanks, quality control samples, and standards mix-
tures were injected to stabilize the system, determine background
ions for the rejection list in data-dependent fragmentation, and
check the quality of the chromatographic runs. Accurate masses
of standards were obtained well within 5 ppm accuracy.
DATA ANALYSIS
Thermo raw data files were checked for the presence of informative
fragmentation spectra in Xcalibur version 2.2. Raw data files were
then converted into mzXML files (using MM_File_Conversion3)3
3http://www.massmatrix.net/mm-cgi/downloads.py
prior to MAGMa analysis (see text footnote 1) (Ridder et al.,
2014b). The MzXML files are available to download in the
supplementary information.
MAGMa settings and analysis
The MzXML files were uploaded to the MAGMa server and
MAGMa default settings were used to annotate urine data-
dependent fragmentation files with compounds present in HMDB
(updated at April 2014), except for a maximum of 2 allowed water
losses (in generated substructures by breaking up to 3 bonds)
and minimum intensity threshold levels of 1,500 counts, and
2% of the base peak for substructure annotation. This annota-
tion is based on the detected precursor masses and the detected
fragments, and produces proposed fragment annotations with a
penalty score that determines the candidate scores and rankings
of candidate metabolites (Ridder et al., 2012). CID (MSn) type
files were handled as in Ridder et al. (2014b). Multiple HCD-MS2
fragmentation spectra of the same precursor ion, recorded at the
different collision energies, were merged by MAGMa as suggested
previously (Horai et al., 2010; Wolf et al., 2010). Each analysis took
3 min or less. Annotated acylcarnitines and carnitine-related com-
pounds were extracted from all the MAGMa annotations in the
results page by applying a filter on the metabolite names (“carni-
tine”) in order to count the number of annotated acylcarnitines in
each run.
Acylcarnitine annotation using the mass fragmentation filter
To scan for compounds that fulfill the defined filter criteria,
extracted ion chromatograms and neutral loss traces were cre-
ated in Xcalibur from the raw data files with a 6 ppm window, to
account for less accurate mass values in the lower m/z range of
fragmentation spectra.
Metabolite annotation
Metabolites were classified as acylcarnitines if the most likely ele-
mental formula matched the mass fragment and neutral loss filter
as described in Section “Acylcarnitine Annotation Using the Mass
Fragmentation Filter.” It should be stressed that this study does
not intend to fully identify the acylcarnitine molecules, but focuses
instead on robust metabolite annotation of acylcarnitines by their
classification while obtaining structural information on the acyl
moiety [i.e., MSI metabolite identification (MSI MI) level 3 (Sum-
ner et al., 2007; Van Der Hooft et al., 2013)]. MSI MI level 2 can be
achieved if the generated fragmentation pattern matched a spec-
tral database spectrum. Full identification would be achievable by
obtaining authentic standards or by elaborate concentration and
purification from the urine matrix, but falls outside the scope of
this study. Scifinder analyses (July 2014) were performed to obtain
the number of candidates for (i) the elemental formula, (ii) the
elemental formula refined with carnitine as substructure, and (iii)
the number of references for the most cited acylcarnitine struc-
ture in Scifinder. In addition, for each annotated acylcarnitine, the
number of HCD fragments between m/z 85 and the fragmented
precursor mass, the number of oxygen atoms in the acylcarni-
tine minus the three oxygen atoms in carnitine, and the C:H ratio
for each annotated acylcarnitine was determined. Additionally, the
presence of matching carnitine metabolites in HMDB was checked
(Table S1 in Supplementary Material).
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The acyl moiety was annotated by searching for and matching
of fragmentation spectra of acylcarnitine reference compounds in
the following databases: METLIN4, mzCloud5, and HMDB6. Fur-
thermore, the HMDB-MAGMa annotation was studied, as well as
the acyl-derived mass fragments and neutral losses. The resulting
metabolite annotations are listed in Table S1 in Supplementary
Material.
RESULTS
We employed a generic metabolite extraction method (Vincent
and Barrett, 2015) with untargeted small metabolite pHILIC and
HILIC profiling approaches (Creek et al., 2011; Zhang et al.,
2012) in combination with HCD-MSMS and CID-MSn frag-
mentations to determine whether robust metabolite annotation
of small polar metabolites could be established using accurate
mass fragmentation spectra. Both pHILIC and HILIC chromatog-
raphy were included in the study to cover the two routinely
used chromatographic separations in our laboratory. As a test
case, we have focused on seeking to enhance the annotation
of acylcarnitines in the complex mixture human urine. Since
acylcarnitines ionize poorly in negative ionization mode, pos-
itive ionization mass spectrometry was employed. Two human
urine extracts (urine extract 1 and 2) were run using the same
pHILIC chromatography, but differing in HCD or CID (MSn)
type fragmentation as specified in the Sections “Methods” and
“HILIC-MS/MS.”
MAGMa ANNOTATION WITH HMDB CANDIDATES OF UNTARGETED
ANALYSIS OF TWO URINE EXTRACTS
From the MzXML files of human urine 1, 615 merged HCD-
MS2 and 461 CID-MSn spectra were read by MAGMa (Rid-
der et al., 2014b), for HCD and CID types of fragmentation,
respectively. A total of 413 and 372 candidates from HMDB
(Wishart et al., 2013), including both known molecules and struc-
tures predicted to be present in human samples, were matched
to 292 and 224 precursor ions, respectively. Supported by the
substructure-based interpretation of fragment spectra in MAGMa,
the annotation of a range of urine metabolites could be con-
firmed. For example, 4-guanidinobutanoic acid (HMDB03464)
and guanidoacetic acid (HMDB00128) were annotated to a
fragmented LC-MS peak, both containing a mass fragment
that indicates the presence of a guanido group. Those acids
are known to be present in human urine. Homocarnosine
(HMDB00745) is another MAGMa annotated compound found
in urine. Interestingly, by using MAGMa we also annotated acetyl-
carnosine (HMDB12881), a compound predicted to be present
in human samples, but not previously observed or confidently
annotated. The dipeptide prolylhydroxyproline (HMDB06695)
was annotated based on its precursor peak and mass frag-
ments, including two hydroxyproline fragments ([C5H8NO3]+
and [C4H6N]+), providing evidence for the prolylhydroxypro-
line configuration over the hydroxylprolyl dipeptide. Similarly,
four predicted isoleucine/leucine containing dipeptides were
4http://metlin.scripps.edu/
5http://www.mzcloud.org
6http://www.hmdb.ca/
annotated, including the isomers alanyl-isoleucine (HMDB28690)
and isoleucyl-alanine (HMDB28900) or their leucine analogs.
Glycerophosphocholine (HMDB00086) was present as a lower
abundance peak in the mass chromatogram, showing distinct frag-
ments for its phosphor-containing fragments. Finally, the anno-
tated l-carnitine (HMDB00062) was one of the major abundant
peaks in the chromatogram.
It should be further noted that 323 and 332 HCD precursors,
and 237 and 245 CID precursors, for urine 1 and 2, respec-
tively, did not match any candidate from HMDB. Currently, the
online HMDB database contains 69 carnitine-related metabolites,
of which 36 are described to be present in human samples, the
remainder being predicted to be present in humans. The MAGMa
metabolite annotation of HMDB compounds to the HCD and
CID fragmentation files of urines 1 and 2 resulted in 12 annotated
acylcarnitine candidates, of which 3 had one or multiple isomers
matched. These candidates included carnitine (HMDB00062) and
3-dehydrocarnitine (HMDB12154). Not all acylcarnitines were
annotated in those four fragmentation files due to (i) the sto-
chastic nature of the data-dependent fragmentation, omitting the
fragmentation of the mass features annotated with propionylcar-
nitine (HMDB00824) and tiglylcarnitine (HMDB02366) in the
CID fragmentation file of urine 2, and (ii) the biological differ-
ences between the two urine files, resulting in different abundance
levels for three annotated acylcarnitines. For example, 2-trans,4-
cis-decadienoylcarnitine (HMDB13325) was three times more
abundant in human urine 1 (1.1E6 vs. 3.3E5 cts), triggering data-
dependent fragmentation in human urine 1, but not in human
urine 2. We note that CID and HCD fragmentation types were
equally informative with respect to HMDB acylcarnitine annota-
tions with MAGMa. Moreover, no other type of structures from
HMDB was matched to the annotated acylcarnitine fragmentation
spectra.
MAGMa ANALYSIS OF pHILIC RUNS FOR FRAGMENT ANNOTATION
AND CONSTRUCTION OF A MASS FRAGMENTATION FILTER TO
CLASSIFY ACYLCARNITINES
In order to determine key fragments or neutral losses (or a com-
bination thereof) that can be used to screen for acylcarnitines,
the fragment annotations as proposed by MAGMa were studied.
Figure 2A shows a screenshot of the fragment list of the HMDB-
annotated tiglylcarnitine (fragments ≥m/z 85) using HCD type
of fragmentation spectra as input. Fragments that yield structural
information from the entire carnitine moiety would offer an ideal
means to classify fragmented acylcarnitine species as it is com-
mon to all members of the class. As can be seen in Figure 2A, a
combination of the mass fragment [C4H5O2]+ and a neutral loss
of C3H9N (i.e., trimethylamine), covers the entire carnitine mol-
ecule, whereas larger carnitine-related fragments, i.e., dehydrated
carnitine, are absent or of low abundance in the fragmentation
spectrum (Figure 2B). Moreover, the mass fragment [C4H5O2]+
and neutral loss C3H9N are the two most intense features of the
spectrum. Further inspection of merged HCD spectra of anno-
tated acylcarnitines in MAGMa showed the fragment [C4H5O2]+
and neutral loss C3H9N to be present in all merged fragmentation
spectra, indicating a combination of those two can be used for
acylcarnitine classification. The fragment annotation as proposed
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B
A
[C4H5O2]
+
C3H9N
FIGURE 2 | (A) Fragment annotation of HMDB-annotated acylcarnitine with
elemental formula C12H21NO4 in MAGMa, annotated as tiglylcarnitine
(HMDB02366), and (B) merged HCD-MS2 spectrum of the annotated
tiglylcarnitine. Arrows indicate the corresponding mass fragmentation
peaks of the neutral loss of trimethylamine (yellow dashed arrow indicates
neutral loss in the mass spectrum; the yellow full arrow points to resulting
mass fragment) and of the mass fragment C4H5O2 (blue full arrow).
by MAGMa for acylcarnitines was also compared to literature
postulations (Yang et al., 2007; Zuniga and Li, 2011) and found
to be consistent.
Using CID fragmentation, the mass fragment [C4H5O2]+
and the neutral loss C3H9N both occurs, as can be seen in
Figure 3 for one annotated acylcarnitine; however, the mass
fragment [C4H5O2]+ is obtained with fivefold lower intensi-
ties compared to HCD fragmentation, whereas the neutral loss
occurs at similar abundance. Moreover, most of the MS3 scans
obtained in CID-MSn did not provide additional fragment infor-
mation, being empty or repeating the MS2 fragment [C4H5O2]+
as in Figure 3B. Thus, based on the comparison of CID-MSn
and HCD-MS2 type of fragmentation for acylcarnitines, the
HCD-MS2 fragmentation was found to be the preferred frag-
mentation type to classify and annotate this class of compounds.
Therefore, the remainder of the study is mostly based on HCD
fragmentation.
Figure 4 shows the CID-MS2 and HCD-MS2 spectra of l-
carnitine obtained by direct infusion of the reference compound
(see Sections “Methods” and “NanoMate Direct Infusion Mea-
surements”), confirming the presence of the mass fragment
[C4H5O2]+ and the neutral loss C3H9N (resulting in C4H7O3;
m/z 103.0390) upon carnitine fragmentation. As in the LC-MS
experiments, the abundance of the key mass fragment is much
FIGURE 3 | MAGMa screenshot of CID-MS2 spectrum (A) and CID-MS3
spectrum (B) of HMDB-annotated tiglylcarnitine. The MS3 scan
originates from the highest abundant MS2 ion. An arrow indicates the
neutral loss of C3H9N, whereas a box captures the C4H5O2 fragment.
lower for the displayed CID-MS2 fragmentation spectrum, sup-
porting HCD as the preferred fragmentation type to classify and
annotate acylcarnitines. Based on the LC-MS and direct infu-
sion experiments, we concluded that in the case of HCD type
fragmentation, a mass fragmentation filter of the fragment mass
[C4H5O2]+ (m/z 85.0284) and a neutral loss of C3H9N (m/z
59.0735) can be used to annotate acylcarnitines; in case of CID-
MSn, the same filter could be applied (valid for acylcarnitines up
to 357 m/z due to the 1/3 cut-off rule as a result of the Ion trap
configuration), but it would work less well for lower abundant
acylcarnitines.
HCD-MS2 FRAGMENTATION SPECTRA: DIFFERENT COLLISION
ENERGIES ARE REQUIRED TO OBTAIN SUFFICIENT STRUCTURAL
INFORMATION FOR CLASSIFICATION AND FURTHER ANNOTATION OF
THE ACYL MOIETY
Low fragmentation energies usually result in the loss of the more
labile side groups of metabolites, such as a carboxyl or hydroxyl
group, whereas higher collision energies tend to break up molecu-
lar structures into smaller, energetically stable fragments (Watson
and Sparkman, 2007). Therefore, the probability of finding a
unique combination of fragments or neutral losses for a spe-
cific metabolite class increases if multiple fragmentation energies
are used. Moreover, it is likely that more structural informa-
tion can be obtained from a combination of different collisional
energies.
Figure 5 shows the low (Figure 5A), middle (Figure 5B), and
high (Figure 5C) energy HCD-MS2 fragmentation spectra for a
novel acylcarnitine structure (i.e., not present in Scifinder) that
was detected and annotated in this study. The three spectra are
clearly different with the neutral loss from the carnitine substruc-
ture present in the low energy spectrum, but not observed at
higher energies. In contrast, the key fragment C4H5O2 observed
at low abundance in Figure 5A is the base peak in the middle
and higher collision energy spectra (Figures 5B,C). The different
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FIGURE 4 | Direct infusion MS/MS data of l-carnitine in CID (top)
and HCD (bottom) mode in the m/z range 50–175. Both energies
(CID@40NCE and HCD@90NCE) represent collision energies where
the key fragment C4H5O2, marked with a blue oval, is an abundant ion
in the respective fragmentation spectra. The yellow dashed arrow
indicates the neutral loss of C3H9N. Boxes indicate where the
fragmentation took place in a schematic representation of the hybrid
mass spectrometer.
energies show complementary fragments derived from the acyl
part of the acylcarnitine molecule, which assists in further struc-
tural characterization. This use of three HCD-MS2 fragmentation
energies resulted in complementary structural information and
enabled detection of both the key neutral loss and fragment that
together form the acylcarnitine mass fragmentation filter and
the detection of structurally informative acyl-derived fragments
(Figures 5 and 6).
APPLICATION OF THE MASS FRAGMENT AND NEUTRAL LOSS FILTER
TO CLASSIFY FRAGMENTED ACYLCARNITINES IN pHILIC-MS AND
HILIC-MS DATA-DEPENDENT FRAGMENTATION RUNS
The initial MAGMa analysis enabled the annotation of the
LC-MS/MS files with candidate acylcarnitine structures from
HMDB and the design of a mass fragmentation filter to clas-
sify acylcarnitines based on the proposed substructure annota-
tions. Subsequently, this filter was applied to the data-dependent
(information dependent, untargeted) HCD fragmentation data
of the two urine extracts run with pHILIC gradients (urine 1
and 2), and two urine extracts run with a HILIC-MS/MS gradi-
ent (urine 3 and 4). This led to the classification of 22 different
acylcarnitines including carnitine itself, 10 of which occurred
as multiple isomers, based on concurrence of the key neutral
loss and the key fragment in the MS2 fragmentation spectra
of detected and fragmented acylcarnitine species. Dehydrocarni-
tine does not display the typical fragmentation as observed for
carnitine and was therefore not classified. The classified acyl-
carnitines ranged from m/z 162.1125 ([M+H]+), identified as
carnitine, to m/z 318.1911 ([M+H]+), annotated as the conju-
gate of suberic acid (octane-1,8-dioic acid) and carnitine (MSI MI
level 3). Notably, out of the 22 annotated acylcarnitines, 11 were
not present in HMDB and were thus previously not annotated
with MAGMa. Furthermore, one candidate acylcarnitine struc-
ture is present in HMDB for four annotated acylcarnitine isomer
pairs.
APPLICATION OF MASS FRAGMENT AND NEUTRAL LOSS FILTER ON
TARGETED FRAGMENTATION SPECTRA OF SUSPECTED LOW
ABUNDANCE ACYLCARNITINE SPECIES DETECTED DURING
UNTARGETED METABOLOMICS
Upon studying full scan HILIC-MS data of extracts 5, 6, and 7
of human urines, 27 masses of potential lower abundant acyl-
carnitine structures not previously fragmented and annotated in
urines 1–4 were included in parent ion lists (see HILIC-MS/MS).
Based on the resulting HCD fragmentations that could be obtained
in sufficient quality for 19 of them, 18 masses were confirmed
www.frontiersin.org March 2015 | Volume 3 | Article 26 | 7
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FIGURE 5 | HCD type MS2 fragmentation spectra obtained at low [30
NCE, (A)], middle [70 NCE, (B)], and high [110 NCE, (C)] energy for
precursor mass 316.2118 m/z, with the proposed elemental formula of
C16H29NO5. The key fragment C4H5O2, marked with a dashed oval, and the
neutral loss C3H9N, indicated by a dashed arrow, occur in the spectra, and this
fragmented metabolite could be annotated as an acylcarnitine.
FIGURE 6 | HCD type MS2 fragmentation spectra obtained at low [30
NCE, (A)], middle [70 NCE, (B)], and high [110 NCE, (C)] energy for
precursor mass 382.2588 m/z, with the proposed elemental formula of
C21H35NO5. The key fragment C4H5O2, marked with a dashed oval, and the
neutral loss C3H9N, indicated by a dashed arrow, occur in the spectra, and this
fragmented metabolite could be annotated as an acylcarnitine.
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to be acylcarnitines. Most of these acylcarnitines had higher
m/z values, i.e., >330 Da, than those annotated during the data-
dependent fragmentation runs. An exception is the acylcarnitine
with elemental formula C13H20NO6 ([M+H]+, m/z 286.1285),
which could be annotated as a conjugate of C6H6O4 [possibly
2-furyl(hydroxy)acetic acid or 2,3-methylenesuccinic acid] and
carnitine (MSI MI level 3).
SCIFINDER ANALYSIS OF ANNOTATED ACYLCARNITINES
Scifinder, a widely used, comprehensive, and well-curated com-
pound database, was used to evaluate the present findings7.
All annotated acylcarnitine formulae were searched in Scifinder,
returning “all hits,” i.e., all Scifinder known structures with that
elemental formula. Subsequently, the refine panel in Scifinder was
used and a substructure search based on the carnitine structure was
performed within all the hits for a given elemental formula, return-
ing “carnitine refined hits.” Finally, if one or more acylcarnitine
structures were returned by Scifinder, the number of “references
to the top hit” was noted as an indication of how well-known the
structure is.
Figure 7 shows histograms of the Scifinder analysis for all 50
annotated acylcarnitines, including those annotated using data-
dependent fragmentation (22), those annotated using a parent ion
list (18), and the annotated acylcarnitine isomers (10). Detailed
figures can be found in Table S1 in Supplementary Material.
Of the 22 acylcarnitines annotated using data from untar-
geted fragmentation, 12 had more than 10 references for the
most cited acylcarnitine structure in Scifinder, indicating that
they are relatively well-studied and characterized. However, accu-
rate mass fragmentation spectra of underivatized forms of these
acylcarnitines are still sparse, since the acylcarnitines were iden-
tified in the references based on either GC-MS or LC-MS data
combined with nominal mass fragmentation. Moreover, 7 of the
22 elemental formulae resulted in 2 or fewer references for the most
7https://scifinder.cas.org/scifinder
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FIGURE 7 | Combined bar plot of the number of annotated
acylcarnitine formulae for: (i) “All hits,” i.e., the number of Scifinder hits
for elemental formulas (EF) of the 50 annotated acylcarnitine formulae,
(ii) “Carnitine refined hits,” i.e., the number of Scifinder hits with the
refinement of a carnitine substructure, and (iii) “References top hit,”
i.e., the number of references to the most cited acylcarnitine (top hit).
cited acylcarnitine structure in Scifinder. For example, no acylcar-
nitine structure with elemental formula C12H18NO5 ([M+H]+,
m/z 256.1179) was present in Scifinder. The corresponding acyl-
moiety with elemental formula C5H4O3 could match four possible
structures in HMDB, with 3-furoic acid (HMDB 004444) being
a likely candidate based on natural abundance in human urine.
However, the HCD spectrum does not indicate the presence of
a furan moiety, nor any other fragment to allow confirmation
of one of the candidate acyl structures. Of the acylcarnitines
annotated using a parent ion list, seven did not yield any hits
in Scifinder with their elemental formula and substructure refine-
ment as input (Table S1 in Supplementary Material). This shows
that targeted (data independent) fragmentation data in combina-
tion with a mass fragmentation filter can be used to structurally
classify observed mass peaks in untargeted mass spectrometry
experiments.
Taking all 50 annotated acylcarnitines together, half of them
have 5 or less references for the most cited acylcarnitine structure,
indicating that few studies could reliably annotate or identify these
acylcarnitines. This Scifinder analysis shows that the presented
workflow yields new knowledge from untargeted metabolomics
experiments by generating data-dependent accurate mass frag-
mentation data and providing robust classification of acylcarnitine
species both present and absent in HMDB.
STRUCTURAL ANNOTATION OF THE ACYL MOIETY
After classification of an acylcarnitine (MSI MI level 3), more
information on the fragmented metabolites can be obtained by
comparison of the obtained fragmentation spectra with data-
base spectra (if present, MSI MI level 2) or studying the frag-
ments derived from the acyl part. The fragmentation data was
analyzed as described in Section “Metabolite Annotation.” This
resulted in three MSI level 2 annotations for acylcarnitines and
their fragmentation data present in MzCloud or Metlin. In addi-
tion, dl-carnitine could be annotated with MSI MI level 1, since
the fragmentation spectrum of the urinary compound matched
with that of an authentic standard. Accurate mass fragmenta-
tion data for the remaining 46 acylcarnitines could not be found;
therefore, acyl-derived mass fragments and neutral losses (from
the suspected acyl-parent ion) were studied. For example, dou-
ble CH2O2 and/or H2O loss appeared to be indicative for a
di-carboxylated acyl moiety, like suberic acid and dodecanedioic
acid. To explore another route to structural annotation of the
acyl moiety, acyl-derived fragments were manually uploaded into
MAGMa to find candidate acyl structures. All annotations of the
studied acylcarnitines can be found in Table S1 in Supplementary
Material.
Three cases are described here in more detail. As described in
Section “Application of the Mass Fragment and Neutral Loss Filter
to Classify Fragmented Acylcarnitines in pHILIC-MS and HILIC-
MS Data-Dependent Fragmentation Runs,” Figure 5 shows the
fragmentation spectra of an acylcarnitine with elemental formula
C16H30NO6 ([M+H]+, m/z 316.2118). Its acyl part is repre-
sented by several fragments at lower fragmentation energy, the
largest being C9H17O3. Neutral losses of H2O and CH2O2 from
this fragment indicate the presence of a carboxyl group within the
www.frontiersin.org March 2015 | Volume 3 | Article 26 | 9
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acyl moiety. In order to obtain candidate structures for the acyl
moiety based on the observed fragments, a list of acyl-derived frag-
ment masses and the suspected “parent mass” was uploaded into
MAGMa, and HMDB and Pubchem were queried using default
MAGMa parameters. The nine resulting HMDB candidates all had
the elemental formula of C9H16O3 but none had a free carboxyl
group. Pubchem resulted in 2,158 candidates (all C9H16O3), with
four hydroxylated C9:1-fatty acids among the top 35 metabolites
(based on candidate scores). Thus, the C16H30NO6 ([M+H]+
acylcarnitine could be annotated as a C9:1-OH-acylcarntine (MSI
MI level 3).
Figure 6 shows the spectra of the annotated acylcarnitine with
elemental formula C21H36NO5 ([M+H]+, m/z 382.2588), which
represents a C14H22O3-carnitine conjugate. The mass fragments
and losses present at lower and higher energies, i.e., the com-
bined loss of C2H6O3 and the mass fragments C12H17 and C9H11
{[Molecular Fragment (MF)]+}, revealed no indicative losses of
a carboxyl group. The acyl moiety likely consists of a branched,
unsaturated alkyl chain, since the ring double bond equivalent of
C14H22O3 is 4. The acyl-derived fragment masses and suspected
parent mass were queried, and HMDB returned one metabolite,
geranyl acetoacetate, with the correct elemental formula; how-
ever, two fragments, C13H19 and C12H17 ([MF]+), could not be
explained by MAGMa based on this structure, and many others
had a high penalty score (≥5). Pubchem, however, returned 1,743
candidate structures with the elemental formula C14H22O3, of
which a 3-hydroxytetradeca-5,8,11-trienoic acid, was listed in the
top 5 (based on candidate scores), and appears to be a plausible
candidate. Therefore, this acylcarnitine could be annotated as a
C14:3-OH-acylcarnitine (MSI MI level 3). Interestingly, several of
the observed fragments in Figures 5A,B (i.e., C7H7, m/z 91.0542;
C7H9, m/z 93.0699; and C7H11, m/z 95.0855, all [MF]+) were
also found in other high mass acylcarnitines (i.e., >330 m/z) at
higher collision energies, indicating similar substructures in the
acyl moiety of these metabolites.
Figure 8 shows the fragmentation spectra of a novel detected
acylcarnitine (i.e., not present in Scifinder) with the elemental for-
mula C17H26NO6 ([M+H]+ and m/z 340.1755), which shows
mass fragments different from most other acylcarnitine spectra
observed in this study. Its conjugated acyl moiety has the elemental
formula of C10H12O4 (which implies five ring double bond equiv-
alents), likely to be caused by the presence of an aromatic ring. Fur-
ther evidence is provided by the fragments C6H7 and C5H6 [MF]+.
A (radical) loss of CH3 was also observed, indicating a methoxy
substitution on the aromatic ring. After collecting the acyl-derived
fragment masses and suspected parent mass, HMDB returned
13 candidates with the elemental formula C10H12O4, of which
2-hydroxy-3-(4-methoxyphenyl)propanoic acid is a potential can-
didate. However, the fragment C7H6O2 (m/z 122.0361 [MF]+)
does not fit well within the structure without breaking the aro-
matic ring. Pubchem yielded 1,520 candidates based on the input
mass fragments, all with elemental formula C10H12O4. Within the
top 20 hits (based on candidate scores), dihydroferulic acid and 5
structurally related isomers were present candidate structures for
the acyl moiety. The fragment C7H6O2 [MF]+ can be explained
with an intact aromatic ring, indicating that the hydroxyl group
FIGURE 8 | HCD type MS2 fragmentation spectra obtained at low [30
NCE, (A)], middle [70 NCE, (B)], and high [110 NCE, (C)] energy for
precursor mass 340.1755 m/z, with the proposed elemental formula of
C17H25NO6. The key fragment C4H5O2, marked with a dashed oval, and the
neutral loss C3H9N, indicated by a dashed arrow, occur in the spectra, and this
fragmented metabolite could be annotated as an acylcarnitine.
Frontiers in Bioengineering and Biotechnology | Bioinformatics and Computational Biology March 2015 | Volume 3 | Article 26 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van der Hooft et al. Enhanced small molecule annotation
is substituted to the aromatic ring. Altogether, this acylcarnitine
could be annotated as conjugate of carnitine and C10H12O4, with a
likely candidate being 3-(4-hydroxy-3-methoxyphenyl)propionic
acid (i.e., dihydroferulic acid) or a structurally related isomer (MSI
MI level 3).
DISCUSSION
This study explored the use of accurate mass fragmentation
approaches in untargeted and targeted HILIC-MS metabolomics
experiments to obtain increased confidence in metabolite anno-
tations. Human urine extracts, representing a complex mixture of
metabolites offered a good test case. Acylcarnitines, metabolites
involved in energy metabolism (Frayn, 2010) are relatively abun-
dant in urine and identified as biomarkers for various related dis-
eases (Adams et al., 2009; Patterson et al., 2009; Luan et al., 2014).
Initial metabolite annotation of candidate metabolites present in
HMDB resulted in the matching of 12 candidate acylcarnitines
to fragmentation data files using the MAGMa interface (Rid-
der et al., 2014b). These annotations then allowed us to define
a mass fragment and neutral loss filter to classify detected and
fragmented acylcarnitines from standard pHILIC and HILIC LC-
MS runs of urine extracts. With the use of this filter in the
context of an untargeted metabolomics experiment, substantially
more acylcarnitines could be reliably annotated from each run,
yielding a total of 50 uniquely classified acylcarnitine species
(including multiple observed isomers) in both untargeted (32)
and targeted (18) fragmentation runs studied (MSI MI level
3). Using our metabolomics platform, these confident annota-
tions were previously not possible; however, using the method-
ology described in this study, we could enhance the annotation
power of our platform for acylcarnitines, and at the same time
collect novel accurate mass fragmentation data for this set of
acylcarnitines.
Previous work showed the value of parent and neutral loss
monitoring in a quadrupole ion trap for targeted screening of
acylcarnitines in biological samples (McClellan et al., 2002; Shige-
matsu et al., 2002; Paglia et al., 2008; Rinaldo et al., 2008). In addi-
tion, several studies applied multiple reaction monitoring (MRM)
type of approaches using the 85 m/z nominal mass fragment or the
neutral loss of 60 to target specifically for acylcarnitines (Maeda
et al., 2008; Kivilompolo et al., 2013; Peng et al., 2013b) or specific
derivatization to probe for acylcarnitines (Minkler et al., 2005). It
should be noted that all the above mentioned targeted approaches
required dedicated sample preparation, used nominal mass spec-
trometers, and in many cases applied derivatization to enhance
the sensitivity of the method. Our study showed that the use
of such parent and neutral loss monitoring within the context
of untargeted high-resolution metabolomics experiments is very
valuable in enabling robust annotations for a biologically relevant
class of metabolites without the use of specific sample extractions,
chromatographic gradients, or complex MRM methods.
Zuniga and Li (2011) reported the most comprehensive study
to date using a similar, but nominal, mass filter for acylcar-
nitine detection, and reported 355 acylcarnitine species (non-
derivatized) in a 2-h UPLC gradient. Unfortunately, these are
not yet included in the HMDB database, and 16 out of the 355
substances reported in the study were added to Scifinder. A possible
reason could be that no definite elemental formulas (EF) were
assigned to all reported acylcarnitines, because the annotations
were made on the basis of nominal mass spectra and postu-
lated fragment structures. In contrast, our approach could provide
more confident annotations based on the accurate mass full scan
and MS2 fragmentation spectra, allowing confident elemental for-
mula assignments and classification as acylcarnitines, as was very
recently underlined by Sumner et al. (2014). Comparison of our
data to the spectra obtained by Zuniga and Li was made, and for
the three presented cases in Figures 5, 6, and 8, the most likely
corresponding acylcarnitines, as monitored and labeled with their
nominal observed mass and isomer letter in their supporting infor-
mation by Zuniga and Li, are 316[E] (fragment 127.1), 382[C]
(fragments 161.3, 119.2, 95.1, and 91.0), and 340[A+B] (frag-
ments 179.2 and 137.0) for annotated acylcarnitines in Figures 5,
6, and 8, respectively (with corresponding fragments to our study
between brackets). It should be noted that the 2-h UPLC gradient
allowed for separation of structurally related acylcarnitines that
were not separated in our 15 (pHILIC) and 30 (HILIC) minute
gradients. All annotated masses in this study could potentially be
matched with nominal masses found in Zuniga and Li’s extensive
study, but a detailed comparison for all annotated acylcarnitines is
hampered by differences in chromatography and mass spectrom-
etry methodology used. An advantage of our approach is the use
of multiple fragmentation energies resulting in both higher-mass
fragments (at low collision energy) and lower-mass fragments (at
high collision energy), creating a unique fingerprint and enabling
further structural characterization of the acyl moiety than in pre-
vious studies. The combination of multiple energies also allowed
more fragments to be detected; and the number of fragments
increased with increasing molecular mass (Figure 9). The num-
ber of fragments has a great impact on the structural information
that can be gathered from a fragmentation spectrum. It should
be added that annotated isomeric acylcarnitines generated similar
fragmentation spectra (see also Section “Limitations of the Cur-
rent Study”). Remarkably, 27 unique acylcarnitine EF returned no
hits upon querying in HMDB; indicating the need for improv-
ing database coverage to facilitate metabolite annotations (see
FIGURE 9 | Scatterplot of the number of fragments counted between
m/z 85 and the mass value of the precursor ion (i.e., fragmented
annotated acylcarnitine) vs. the theoretical mass value of the
acylcarnitine in positive ionization mode.
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Compound and Spectral Databases for Metabolite Annotation).
Therefore, alternative ways to characterize the structure of the acyl
moiety were explored in this study. We compared fragmentation
spectra to spectral databases and by studying neutral losses and
using MAGMa to find candidate metabolites (see Scifinder Analy-
sis of Annotated Acylcarnitines), thereby revealing the unexpected
acyl moiety dihydroferulic acid or a structurally related isomer for
one of the annotated acylcarnitines (Table S1 in Supplementary
Material).
ADVANTAGES OF USING MAGMa FOR INITIAL ANNOTATION OF URINE
EXTRACTS WITH HDMB CANDIDATES
• MAGMa annotation of the LC-MS fragmentation data with
candidates from an appropriate database [in this study HMDB
(Wishart et al., 2013)], provided a quick overview of a diverse
range of candidate metabolites present in the urine extracts.
• The fragment annotations proposed by MAGMa helped to
quickly recognize specific fragmentations of acylcarnitines.
ADVANTAGES OF USING AN ACCURATE MASS FRAGMENTATION
FILTER TO CLASSIFY COMPOUNDSWITHIN THE CONTEXT OF
UNTARGETED METABOLOMICS EXPERIMENTS
• Measurement of fragmentation data in untargeted metabolite
profiling experiments allows MSI MI level 3, and sometimes 2,
annotations where otherwise only level 4 would be possible. A
similar trend was previously observed for CID-MSn approaches
applied to plant secondary metabolites (Van Der Hooft et al.,
2012b).
• Accurate fragment mass values allow more reliable elemental
formula assignments of the fragment ions and molecular ions,
resulting in more reliable metabolite annotations (Sumner et al.,
2014).
• Acylcarnitines were reliably annotated in urine datasets that also
contain fragmentation data of many other metabolite classes
like amino acids and purines. This allows different classes of
metabolites to be studied in the same datasets using the same
approach.
LIMITATIONS OF THE CURRENT STUDY
• Sample preparation and chromatography used were generic and
not optimized for acylcarnitine detection, resulting in a lesser
chromatographic resolution for acylcarnitines than obtained in
some other others targeting acylcarnitines, e.g., Zuniga and Li
(2011) and Gucciardi et al. (2012).
• The data-dependent fragmentation approach in combination
with the mass fragmentation filter did not result in annota-
tion of all studied acylcarnitines, as for 18 lower abundant
acylcarnitines a targeted fragmentation approach was needed
to obtain fragmentation spectra enabling their classification as
acylcarnitines.
• Chromatographically separated, isomeric acylcarnitines (shar-
ing the same elemental formula) could not be discriminated
based on their fragmentation patterns and need additional spec-
tral information (e.g., NMR spectroscopy) to confidently dis-
criminate them. This phenomenon is commonly observed in
mass spectrometry data, especially for stereoisomers, with some
exceptions to this rule (Van Der Hooft et al., 2011).
COMPOUND AND SPECTRAL DATABASES FOR METABOLITE
ANNOTATION
Our metabolite annotation would benefit from an increased cov-
erage in compound databases (like HMDB) and spectral databases
(like mzCloud, Metlin, and MassBank). The availability of more
fragmentation spectra of reference compounds would facilitate
the design of more mass fragmentation filters such as the one
described in our study. Despite the fact that the MzCloud database
(see text footnote 5) and Massbank8 provide fragmentation data
for many reference compounds, often in both ionization modes,
at different energies, and from different instruments, MzCloud
and Massbank contain spectral data for only 5 and 7 acylcarni-
tine structures, respectively, which is a small number compared
to the 50 annotated in our study. In fact, in our study, only 3 of
the reported acylcarnitines could be matched to database frag-
mentation spectra searched for in different spectral databases,
“upgrading” the level 3 annotation to level 2, apart from carni-
tine, for which we could obtain in-house reference data allowing
for a MSI MI level 1 identification. We also applied LipidSearch
(ThermoScientific software) to our fragmentation data, but the
software did not return any acylcarnitine candidates matched
to the fragmentation data. Furthermore, as mentioned before,
HMDB does not cover the majority of acylcarnitine EF annotated
in this study. Emerging metabolite annotation software tools like
MAGMa will benefit from an increased coverage of compound
databases such as HMDB since they serve as input for candidate
metabolites. Finally, standardization of metabolomics data report-
ing, as promoted by COSMOS9 and MetaboLights and the MSI
initiative (Sumner et al., 2007, 2014; Salek et al., 2013a,b) will allow
metabolomics researchers to (i) build on each other’s findings in
method development and data analysis by easier exchange of data
and protocols, and (ii) facilitate the search for earlier reported
annotated metabolites and their spectral data, thereby facilitating
metabolite annotations of present and future studies.
FUTURE RESEARCH DIRECTIONS
Implementation of mass fragmentation approaches into rou-
tine untargeted high-resolution metabolomics experiments would
benefit from: (i) finding a working compromise for the coverage
of uniquely fragmented metabolites and the need for multiple
energies or fragmentation depths (and thus scan cycle times); and
(ii) creating more mass fragmentation filters to classify metabo-
lite features and support robust metabolite annotation, thereby
reducing the number of MSI MI level 4 annotations in untargeted
metabolomics experiments:
(i) Data-dependent fragmentation is a stochastic process, result-
ing in mass peaks to be fragmented in one run and not in
another. The use of different collision energies for HCD frag-
mentation proved to be essential to get as much structural
information as possible on the annotated acylcarnitines (see
HCD-MS2 Fragmentation Spectra: Different Collision Ener-
gies are Required to Obtain Sufficient Structural Information
for Classification and Further Annotation of the Acyl Moiety),
8http://www.massbank.jp/
9http://cosmos-fp7.eu/
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and is important in untargeted mass spectrometry to get struc-
tural information on diverse set of compounds present in
biological extracts (Madala et al., 2012). There is a compromise
between the number of compounds for which fragmentation
data can be acquired and the amount of fragment data gen-
erated per compound. Very recently, several ways to improve
coverage of fragmented masses during data-dependent analy-
sis have been postulated, i.e., by using gas-phase fractionation
(Calderón-Santiago et al., 2014), by so-called SWATH analysis
(Roemmelt et al., 2014) through “delayed fragmentation” as
was proposed for peptide fragmentation in proteomics (Sav-
itski et al., 2011), or by a combination of data dependent
and independent fragmentation approaches (Hoffmann et al.,
2014). It should be noted that some of those fragmentation
strategies require sophisticated tools to analyze the resulting
data sets as a result of multiple precursor ions being simulta-
neously fragmented. Therefore, extension of this work will be
primarily focused on finding the optimal compromise between
metabolite coverage and structural information using narrow
isolation windows.
(ii) The present findings showed that metabolite classification
(i.e., fatty acids, imidazole-containing, carnitine-related, etc.)
based on key mass fragments and neutral losses is a promising
approach within the context of untargeted mass spectrome-
try. Moreover, the approach not only enables more complete
annotations within complex metabolomics datasets but also
reduces the number of candidate metabolites to be considered
for a detected mass feature, e.g., based on database queries on
elemental formula, from more than 100 to only a handful (see
Figure 7 and Table S1 in Supplementary Material). Organic
molecules consist of recurring subunits, often decorated with
different side groups and chains. Therefore, future work will
aim to derive more relevant structural key mass fragments
and neutral losses for other classes of compounds present in
complex biological samples, like human urine, by integrating
expert knowledge and automated approaches.
CONCLUSION
Metabolite classification based on a specific set of observed frag-
ments and neutral losses proved to be a successful approach in
enabling robust annotations of mass peaks observed in untargeted
mass spectrometry. MAGMa can successfully annotate acylcar-
nitine structures present in HMDB to fragmented acylcarnitine
masses in complex biological samples. Based on the acylcarnitine
CID and HCD fragment and neutral loss annotation, a selective
mass fragmentation filter was constructed. Application of that fil-
ter to HCD fragmentation data obtained using data dependent
and targeted fragmentation methods led to the annotation of
50 urinary acylcarnitines of which most had not been reliably
annotated before using a high-resolution HILIC-MS approach.
The annotation approach we describe shows that within the
context of untargeted high-resolution mass spectrometry based
metabolomics experiments, reliable metabolite annotations can be
achieved using standard, high-throughput untargeted approaches
in combination with mass fragmentation filters that allow for
metabolite classifications.
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The Supplementary Material for this article can be found
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00026/abstract. All mzXML files of human urine extracts 1–7
that associated with this study are publicly available from the
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Table S1 | Overview of acylcarnitines including spectral properties and
Scifinder analysis. The rows represent the annotated acylcarnitine metabolites
(including carnitine), and the rows (left to right) represent: the human urine
extract number for which the scan number and retention time are noted in the
Table (Urine file fragm); the scan number of the full scan in which the
acylcarnitine is precursor ion (# MS1); the retention time in minutes (RT); the
theoretical mass of the ionized acylcarnitine (m/z [M+H]+); the elemental
formula of the ionized acylcarnitine (EF [M+H]+); the number of hits Scifinder
returns on querying the (neutralized) elemental formula of the acylcarnitine (Hits
Scifinder); the number of hits in Scifinder remainin after refining based on the
(decharged) substructure of carnitine (Refine: Carnitine); the number of
references to the most cited acylcarnitine returned by Scifinder (# refs Top hit);
the number of fragments counted between m/z 85 and the precursor ion (#
fragm 85 – precurs); the number of oxygen atoms in the acylcarnitine minus the
three carnitine oxygen atoms (# O atom minus 3); the carbon to hydrogen ratio
(C:H), the presence (Y) or absence (N) of the annotated acylcarnitines in HMDB
(Present in HMDB?); the annotation/identification of reported acylcarnitines,
using the nomenclature of Zuniga and Li (2011) for acylcarnitines not present in
databases (Annotation/Identification); the Metabolomics Standard Initiative
Metabolite Identification level of the reported acylcarnitines (MSI MI level);
information on the metabolite annotation process (Spectra compared
to/fragment analysis); and the SMILES string for level 2 or 1 identified structures
(SMILES).
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